XML 62 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue Recognition	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition During the three months ended March 31, 2020, the Company recognized total revenue under collaborative research and development and other agreements of $1.1 million from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), $72,000 from AstraZeneca and $115,000 from various other contracts. Of the total revenue recognized during the three months ended March 31, 2020, $58,000 was in deferred revenue as of December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration